RV 138; B011

A Phase I Study of Sanofi Pasteur Live Recombinant ALVAC-HIV (vCP205, HIV-1 Env/Gag/Pol) in Seronegative Adults Administered (1) Subcutaneously Via Ex Vivo Transfected, Autologous Dendritic Cells, (2) Intradermally, or (3) Intramuscularly

Trial Details:

I Completed
Walter Reed Army Institute of Research (WRAIR), U.S. Military HIV Research Program (MHRP) March 01, 2006
ALVAC-HIV MN120TMG strain (vCP205)
ALVAC-HIV MN120TMG strain (vCP205) Viral Vector - Pox
USA 36